Peroxisome proliferator-activated receptor agonists and bladder cancer: lessons from animal studies.
about
Diabetes and gastric cancer: the potential linksThiazolidinediones and the promise of insulin sensitization in type 2 diabetes.Metformin reduces thyroid cancer risk in Taiwanese patients with type 2 diabetes.Rosiglitazone may reduce non-melanoma skin cancer risk in TaiwaneseAntiproliferative effects and molecular mechanisms of troglitazone in human cervical cancer in vitro.Assessing Bladder Cancer Risk in Type 2 Diabetes Clinical Trials: the Dapagliflozin Drug Development Program as a 'Case Study'Human insulin does not increase bladder cancer risk.Biological Rationale for the Use of PPARγ Agonists in GlioblastomaRosiglitazone reduces breast cancer risk in Taiwanese female patients with type 2 diabetes mellitus.Sitagliptin may reduce prostate cancer risk in male patients with type 2 diabetes.Scientific Evidence and Controversies About Pioglitazone and Bladder Cancer: Which Lessons Can Be Drawn?A review on thiazolidinediones and bladder cancer in human studies.Thiazolidinediones under preclinical and early clinical development for the treatment of Parkinson's disease.An updated review on cancer risk associated with incretin mimetics and enhancers.Thiazolidinedione drugs in the treatment of type 2 diabetes mellitus: past, present and future.Peroxisome proliferator-activated receptor (PPAR) α and δ activators induce ICAM-1 expression in quiescent non stimulated endothelial cells.PPAR-γ agonist attenuates inflammation in aortic aneurysm patients.Pioglitazone does not increase the risk of type II diabetes in patients with bladder cancer: A retrospective study.Rosiglitazone may reduce thyroid cancer risk in patients with type 2 diabetes.Opposite Interplay Between the Canonical WNT/β-Catenin Pathway and PPAR Gamma: A Potential Therapeutic Target in Gliomas.
P2860
Q24602836-3E9FACFF-CF43-4547-8D55-E6EAA90929E4Q34315432-5C7D1064-257D-459E-81EC-6E79A9BD321FQ34323510-0398E96F-27EA-4A41-92D0-4A2D3DDCD3EAQ35077354-7732A7AF-7C9C-4935-B89F-E44EEA3F3C1AQ35659287-708B9E1A-3367-4C1F-B1BC-43F8DFF5B60FQ36073447-D845C9E2-A7E0-4DF6-994A-742A508C955CQ37496102-9D94A90C-DDC9-41AA-AD3A-8E0A8A1FBD68Q37636459-FC7A2335-EFE0-4DD0-B86E-3EEAA31976CDQ37709423-94CD987C-0983-420D-89DB-CCDCF9D3F342Q37745926-B69FF104-47AA-40D3-82DB-015CD49C35F0Q38122640-3CE93D50-4593-4460-B1A9-A2AABE0D4595Q38193601-0875475A-2597-4352-9578-EED62656B5D9Q38250185-AB51B2FF-06E0-432B-AF94-9956B33ECC42Q38388920-745DB56A-ADE0-416F-9D2D-3D19C398FDF5Q38641190-C89960A0-17FB-4E95-A89A-973F24EC0C8DQ39468345-07954684-13EA-4BA4-BE0D-903229C95535Q40693751-0600E2AF-B3D9-4730-8186-B4E6D9B50501Q42137557-0EDB1AD5-2D98-4BF6-B172-6AAC7E261305Q43665499-630B0F0A-0237-4E9D-89DD-34826A41B12BQ55457391-8591E7E1-02EC-49FC-9FBC-1061BF92D6DA
P2860
Peroxisome proliferator-activated receptor agonists and bladder cancer: lessons from animal studies.
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
Peroxisome proliferator-activa ...... : lessons from animal studies.
@en
type
label
Peroxisome proliferator-activa ...... : lessons from animal studies.
@en
prefLabel
Peroxisome proliferator-activa ...... : lessons from animal studies.
@en
P2860
P1476
Peroxisome proliferator-activa ...... : lessons from animal studies.
@en
P2093
Chin-Hsiao Tseng
Farn-Hsuan Tseng
P2860
P304
P356
10.1080/10590501.2012.735519
P577
2012-01-01T00:00:00Z